Global

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Exploring the market’s emergence on the global stage.

Fresh round of discussions around health technology assessment.

Efforts for a standardized approach coming to a head in Europe.

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Increase in new treatments also brings increase in logistical challenges for pharma.

Assessing the road ahead for Chinese biotech.

Opportunity remains despite regulatory and access obstacles.

Licensing deals, strategy, and COVID among factors to consider for companies entering Chinese pharma M&A.

Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.

With a strong pharma background that includes bringing non-US biotechs stateside in the rare diseases space, Rami Levin, CEO of Saniona, talks about the importance of growing his company’s business and his dedication to that mission.

European Commission looks to relieve issues without legislation.

Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.

Looks to address disconnect between registration and reimbursement.

2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.

China‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.

Novo Nordisk announces plans to invest more than 17bn Danish kroner constructing three new manufacturing facilities in Kalundborg, Denmark.​

Lack of IP management plagues recent regulatory discussions.

As EU brand leaders build their omnichannel customer engagement strategies, they need to address challenges in the European environment with a well-thought-out deployment plan.

To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.

The Identification of Medicinal Products (IDMP) software industry has talked up the broader potential of data-driven processes. Pharma companies and their software providers have an important role to play in realizing these processes. Frits Stulp discusses the foundations that need to be laid for lasting transformation of pharma information access in the real world.

The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.

Committee struggles to find a common treatment approach.

Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.

Rebrand launched to design, develop, and deliver specialist training, skills assessments and process consultancy to the healthcare and pharma industries.